Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Hospital Düsseldorf, Germany.
Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria; Division of Cardiology, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
J Crit Care. 2020 Dec;60:58-63. doi: 10.1016/j.jcrc.2020.07.024. Epub 2020 Aug 1.
The approach to limit therapy in very old intensive care unit patients (VIPs) significantly differs between regions. The focus of this multicenter analysis is to illuminate, whether the Clinical Frailty Scale (CFS) is a suitable tool for risk stratification in VIPs admitted to intensive care units (ICUs) in Germany. Furthermore, this investigation elucidates the impact of therapeutic limitation on the length of stay and mortality in this setting.
German cohorts' data from two multinational studies (VIP-1, VIP-2) were combined. Univariate and multivariate logistic regression were used to evaluate associations with mortality.
415 acute VIPs were included. Frail VIPs (CFS > 4) were older (85 [IQR 82-88] vs. 83 [IQR 81-86] years p < .001) and suffered from an increased 30-day-mortality (43.4% versus 23.9%, p < .0001). CFS was an independent predictor of 30-day-mortality in a multivariate logistic regression model (aOR 1.23 95%CI 1.04-1.46 p = .02). Patients with any limitation of life-sustaining therapy had a significantly increased 30-day mortality (86% versus 16%, p < .001) and length of stay (144 [IQR 72-293] versus 96 [IQR 47.25-231.5] hours, p = .026).
In German ICUs, any limitation of life-sustaining therapy in VIPs is associated with a significantly increased ICU length of stay and mortality. CFS reliably predicts the outcome.
在非常年老的重症监护病房患者(VIP)中,限制治疗的方法在不同地区有很大差异。这项多中心分析的重点是阐明临床虚弱评分(CFS)是否适合作为德国重症监护病房(ICU)收治的 VIP 患者进行风险分层的工具。此外,本研究还阐明了在此情况下治疗限制对住院时间和死亡率的影响。
合并了两项多国研究(VIP-1、VIP-2)的德国队列数据。采用单因素和多因素逻辑回归分析评估与死亡率的相关性。
共纳入 415 例急性 VIP。虚弱的 VIP(CFS>4)年龄更大(85 [IQR 82-88] 岁 vs. 83 [IQR 81-86] 岁,p<0.001),30 天死亡率更高(43.4% 与 23.9%,p<0.0001)。在多因素逻辑回归模型中,CFS 是 30 天死亡率的独立预测因素(aOR 1.23,95%CI 1.04-1.46,p=0.02)。任何生命支持治疗限制的患者 30 天死亡率显著增加(86% 与 16%,p<0.001)和住院时间(144 [IQR 72-293] 与 96 [IQR 47.25-231.5] 小时,p=0.026)。
在德国 ICU 中,任何 VIP 患者生命支持治疗的限制都与 ICU 住院时间和死亡率的显著增加相关。CFS 可靠地预测结局。